- Home
- BPOP vs CORT Comparison
BPOP vs CORT Comparison
Compare BPOP & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPOP | CORT |
|---|---|---|
| Founded | 1893 | 1998 |
| Country | United States | United States |
| Employees | 9406 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | BPOP | CORT |
|---|---|---|
| Price | $128.98 | $33.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $148.60 | $105.20 |
| AVG Volume (30 Days) | 474.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $11.33 | $29.97 |
| Revenue Next Year | $6.02 | $30.25 |
| P/E Ratio | ★ $11.87 | $40.98 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $78.23 | $28.66 |
| 52 Week High | $149.31 | $117.33 |
Technical Indicators
Market Signals| Indicator | BPOP | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 33.92 |
| Support Level | $122.73 | $33.53 |
| Resistance Level | $129.09 | $41.92 |
| Average True Range (ATR) | 4.42 | 1.67 |
| MACD | -1.93 | 0.24 |
| Stochastic Oscillator | 6.59 | 14.66 |
Price Performance
Historical ComparisonAbout BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.